1 Sex-specific metabolic pathways associate with Alzheimer's Disease (AD)

2 endophenotypes in the European Medical Information Framework for AD

3 Multimodal Biomarker Discovery cohort

4

5 Jin Xu^{1,2}, Rebecca Green^{2,3}, Min Kim^{4, +}, Jodie Lord², Amara Ebshiana¹, Sarah Westwood⁵,
6 Alison L Baird⁵, Alejo J Nevado-Holgado⁵, Liu Shi⁵, Abdul Hye², Stuart G. Snowden^{1,+,}
7 Isabelle Bos^{6,7}, Stephanie J. B. Vos⁷, Rik Vandenbergh⁶, Charlotte E. Teunissen⁸, Mara Ten
8 Kate^{6,8}, Philip Scheltens⁶, Silvy Gabel^{9,10,11}, Karen Meersmans^{10,11}, Olivier Blin¹², Jill
9 Richardson¹³, Ellen Elisa De Roeck^{14,15}, Sebastiaan Engelborghs^{15,16}, Kristel Slegers^{17,18}, Régis
10 Bordet¹⁹, Lorena Rami²⁰, Petronella Kettunen²¹, Magda Tsolaki²², Frans R.J. Verhey²³, Daniel
11 Alcolea²⁴, Alberto Lleó²⁴, Gwendoline Peyratout²⁵, Mikel Tainta²⁶, Peter Johannsen²⁷, Yvonne
12 Freund-Levi^{28,29}, Lutz Frölich³⁰, Valerija Dobricic³¹, Giovanni B. Frisoni^{32,33}, José Luis
13 Molinuevo^{34,35}, Anders Wallin²¹, Julius Popp^{36,37}, Pablo Martinez-Lage³⁸, Lars Bertram^{39,40}, Kaj
14 Blennow^{41,42}, Henrik Zetterberg^{41,43,44,45}, Johannes Streffer¹⁵, Pieter Jelle Visser^{46,47}, Simon
15 Lovestone^{5,48}, Petroula Proitsi^{2, *}, Cristina Legido-Quigley^{1,4, *}, and on behalf of EMIF
16 Consortium

17

18 (1)Institute of Pharmaceutical Science, King's College London, London, United Kingdom, (2)Institute
19 of Psychiatry, Psychology and Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's
20 College London, London, United Kingdom, (3) NIHR Maudsley Biomedical Research Centre, South
21 London and Maudsley NHS Trust, London, United Kingdom, (4)Steno Diabetes Center, Gentofte,
22 Denmark, (5)Department of Psychiatry, University of Oxford, Oxford, United Kingdom, (6)Department
23 of Neurology, Alzheimer Center Amsterdam, Amsterdam Neuroscience, Vrije Universiteit Amsterdam,
24 Amsterdam, Netherlands, (7)Department of Psychiatry and Neuropsychology, School for Mental Health
25 and Neuroscience, Alzheimer Centrum Limburg, Maastricht University, Maastricht, Netherlands,
26 (8)Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam,
27 Netherlands, (9)Department of Clinical Chemistry, Neurochemistry Laboratory, Amsterdam
28 Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, Netherlands,
29 (10)Department of Neurosciences, Laboratory for Cognitive Neurology, Leuven, Belgium,
30 (11)University Hospital Leuven, Leuven, Belgium, (12)Aix-Marseille University-CNRS, Marseille,
31 France, (13)Neurosciences Therapeutic Area, GlaxoSmithKline R&D, Stevenage, United Kingdom,
32 (14)Vrije Universiteit Brussel, Brussels, Belgium, (15)Reference Center for Biological Markers of
33 Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium, (16)
34 Department of Neurology and Center for Neurosciences (C4N), UZ Brussel and Vrije Universiteit
35 Brussel (VUB), Brussels, Belgium, (17)Institute Born-Bunge, University of Antwerp, Antwerp,
36 Belgium, (18) Complex Genetics of Alzheimer's Disease Group, VIB Center for Molecular Neurology,
37 VIB, Antwerp, Belgium, (19)Université de Lille, Lille, France, (20)Alzheimer's Disease and Other
38 Cognitive Disorders Unit, Hospital Clínic of Barcelona, IDIBAPS, Barcelona, Spain, (21) Institute of
39 Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

(22)AHEPA University Hospital, Thessaloniki, Greece, (23)Alzheimer Center Limburg, School for Mental Health and Neuroscience, Maastricht University, Maastricht, Netherlands, (24) Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, (25)Lausanne University Hospital, Lausanne, Switzerland, (26) Fundación CITA-Alzhéimer Fundazioa, San Sebastian, Spain, (27) Danish Dementia Research Centre, Rigshospitalet, Copenhagen, Denmark, (28) Department of Neurobiology, Caring Sciences and Society (NVS), Division of Clinical Geriatrics, Karolinska Institutet, Department of Psychiatry in Region Örebro County and School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden, (29) Department of Old Age Psychiatry, Psychology & Neuroscience, King's College, London, UK, (30) Department of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany, (31) Lübeck Interdisciplinary Platform for Genome Analytics, Institutes of Neurogenetics and Cardiogenetics, University of Lübeck, Lübeck, Germany, (32) University of Geneva, Geneva, Switzerland, (33) IRCCS Fatebenefratelli, Brescia, Italy, (34) Barcelona Beta Brain Research Center, Universitat Pompeu Fabra, Barcelona, Spain, (35) University of Lille, Lille, France, (36) Old Age Psychiatry, Department of Psychiatry, University Hospital Lausanne, Lausanne, Switzerland, (37) Department of Geriatric Psychiatry, University Hospital of Psychiatry Zürich, Zürich, Switzerland, (38) Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, San Sebastian, Spain, (39) University of Oslo, Oslo, Norway, (40) University of Lübeck, Lübeck, Germany, (41) Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden, (42) Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal, Sweden, (43) Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden, (44) UK Dementia Research Institute at UCL, London, United Kingdom, (45) Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom, (46) Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, Netherlands, (47) Alzheimer Center Amsterdam, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Netherlands, (48) Janssen-Cilag UK Ltd, Oxford, United Kingdom, ⁺Present address - Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Denmark, ⁺⁺Present address –Department of Biological Sciences, Royal Holloway, University of London, London, United Kingdom.

Key words: sex, Alzheimer's disease, metabolomics, metabolic pathway, blood, vanillylmandelate, tryptophan betaine

Conflicts of interest: KB and HZ have served as consultants at scientific advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, NovartisEisai, Denali, Roche

77   Diagnostics, and Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics,
78   Nervgen, AZTherapies and CogRx, have given lectures in symposia sponsored by
79   Cellectricon, Fujirebio, Alzecure and Biogen, and are co-founders of Brain Biomarker
80   Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator
81   Program (outside the submitted work).
82   DA participated in advisory boards from Fujirebio-Europe and Roche Diagnostics and
83   received speaker honoraria from Fujirebio-Europe, Roche Diagnostics, Nutricia, Krka
84   Farmacéutica S.L. and Esteve Pharmaceuticals S.A.
85   The other authors declare no conflict of interest.

Abstract

BACKGROUND: Physiological differences between males and females could contribute to the development of AD. Here, we examined metabolic pathways that may lead to precision medicine initiatives.

METHODS: We explored whether sex modifies the association of 540 plasma metabolites with AD endophenotypes including diagnosis, CSF biomarkers, brain imaging, and cognition using regression analyses for 695 participants (377 females), followed by sex-specific pathway overrepresentation analyses, *APOE* ϵ 4 stratification and assessment of metabolites' discriminatory performance in AD.

RESULTS: In females with AD, vanillylmandelate (tyrosine pathway) was increased and tryptophan betaine (tryptophan pathway) was decreased. The inclusion of these two metabolites (AUC = 0.83, SE = 0.029) to a baseline model (covariates + CSF biomarkers, AUC = 0.92, SE = 0.019) resulted in a significantly higher AUC of 0.96 (SE = 0.012). Kynurenate was decreased in males with AD (AUC = 0.679, SE = 0.046).

CONCLUSIONS:

Metabolic sex-specific differences were reported, covering neurotransmission and inflammation pathways with AD endophenotypes. Two metabolites, in pathways related to dopamine and serotonin, associated to females, paving the way to personalised treatment.

1 Background

Alzheimer's disease (AD) is the most common neurodegenerative dementia, making it a major source of global morbidity and mortality. Current clinical diagnosis of AD relies on a battery of cognitive tests combined with structural and functional imaging and cerebrospinal fluid (CSF) biomarkers (1). Studies on mechanisms and biomarkers of AD are attracting considerable interest due to the challenge of diagnosing cognitively normal people during the preclinical phase of the disease.

Biomarkers of AD can be described in the ATN framework, grouped into those of β amyloid ($A\beta$) deposition, pathological tau, and neurodegeneration (2). This ATN descriptive classification system is independent to clinically defined diagnostic criteria and eases the categorisation of multidomain biomarker findings at the individual level (3). $A\beta$ (measured by CSF $A\beta_{42/40}$ or amyloid PET or CSF $A\beta_{42}$) and tau (evaluated by CSF phosphorylated tau or tau PET) are being refined as the primary mediators of AD-related synaptic loss and eventual neuronal death (4). AD neurodegeneration or neuronal injury can be quantitatively or topographically estimated by CSF t-tau, [^{18}F] fluorodeoxyglucose-positron emission tomography (FDG-PET), or structural MRI (5). Although there are challenges of measuring biomarkers for brain diseases in the blood (low concentrations and expression in non-cerebral tissues), blood-based biomarkers are easily accessible, minimally invasive and scalable for large scale use. Recently, success in detecting AD and predicting future disease progression has been achieved

particularly for the application of glial fibrillary acidic protein (GFAP), plasma phospho-tau181 and phospho-tau217 (6–8).

Additionally to the above-mentioned biomarkers, AD risk factors include age, as well as genetic, environmental and modifiable lifestyle factors (9). Sex-related differences in brain structure and function have also been widely discussed (10,11), and if we know more about whether sex-specific associations exist and the biological underpinnings of these relationships, this may help guide more personalised treatments (12). Studies have suggested that females are at greater risk for developing AD when compared to males. The UK dementia report states that more females have AD and that this trend is likely to remain with a F:M ratio of approximately 2 to 1 in the projected dementia incidence for 2051 (13). Although it has been recently reported that selective survival may contribute to sex/gender differences in dementia incidence, this does not preclude the additional contributions from biological mechanisms (14).

Our previous studies using smaller cohorts have shown that i) plasma metabolites have the potential to match the AUC of well-established AD CSF biomarkers through machine learning approach (sample size N = 357) and ii) primary fatty amides were associated with AD endophenotypes (sample size N = 593) (15,16). In the present study, we performed metabolomics in 102 additional participants to a total of 695 and aimed to explore whether sex modifies the association of plasma metabolites with AD

151 endophenotypes. Linear and logistic regressions were performed to investigate the
 152 association of plasma metabolite levels with AD endophenotypes (CSF biomarkers,
 153 brain MRI, cognition measures and diagnosis) in the full cohort including a sex
 154 interaction term, followed by sex-stratified analyses and pathway analyses. Prediction
 155 models based on logistic and linear regression were then built to assess AD biomarker
 156 performance in each sex stratum. The study design is illustrated in Supplementary
 157 Figure S1.

2 Methods

2.1 Participants

This study included 695 participants consisting of 377 females and 318 males from the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery (EMIF-AD MBD) (17). There were 283 control (CTL) participants, 275 participants with mild cognitive impairment (MCI) and 137 AD dementia patients. Participants were included from three multicenter studies: EDAR (n = 84) (18), PharmaCog (n = 40) (19), DESCRIPA (n = 16) (20), and eight single center studies: Amsterdam (n = 147) (21), Antwerp (n = 133) (22), IDIBAPS (n = 93) (23), Leuven (n = 53) (24), San Sebastian GAP (n = 40) (25), Barcelona-Sant Pau (n = 35) (26), Gothenburg (n = 34) (27), Lausanne (n = 20) (28).

2.2 Clinical and cognitive data

Neuropsychological tests measuring five different cognitive domains were available. Briefly, these were memory (delayed and immediate), language, attention, executive function, and visuo-construction (Table 1). Hippocampal volume (left, right and sum, adjusted for intracranial volume ICV) and cortical thickness (average across the whole brain and in AD signature regions) were also available (Table 1). The definition of CTL was a normal performance on neuropsychological assessment (within 1.5 SD of the average for age, gender and education). MCI was defined as having cognitive complaints and performance below 1.5 SD of the average on at least one

neuropsychological test but no dementia (29). AD-type dementia diagnosis was made based on a clinical diagnosis, using the National Institute of Neurological and Communicative Disorders and Stroke – Alzheimer’s Disease and Related Disorders Association criteria (30). Details on the neuropsychological test, amyloid (CSF A β _{42/40} ratio of the central analyses or the local CSF A β ₄₂ value or the standardized uptake value ratio (SUVR) on an amyloid-PET scan) and tau level measurements, magnetic resonance imaging (MRI) and genetic analyses can be found in Bos *et al.* (17).

2.3 Metabolomics data

Relative levels of 665 plasma metabolites were measured in fasted blood samples by *Metabolon, Inc.* Metabolomics experiments were performed with an additional 102 participants, and details of the analytical method for all (N=695) can be found in Kim *et al.* (16). After removing metabolites with more than 20% missing values, 540 metabolites with known identity were included for further analyses. Log10 transformation and scaling (mean of zero and standard deviation of one) were applied to metabolomics data after missing values were imputed with the k-nearest neighbour algorithm (k=10, “impute” package for R). Single outlying values beyond three standard deviations were further removed.

2.4 Statistical analyses

Prior to statistical analyses, baseline characteristics were compared among the three diagnostic groups using the ANOVA for continuous variables and Chi-square test for categorical variables (Table 1). The 15 AD endophenotypes were classified into four collections: CSF biomarkers (three continuous variables; A β , p-tau, t-tau), brain MRI measurements (five continuous variables; hippocampal left, right and sum volume, average cortical thickness in whole brain and AD regions), cognition measures (six continuous variables; attention, executive, language, memory delay, memory immediate, visuoconstruction) and diagnosis (one binary variable; AD versus CTL, MCI excluded).

Regression analyses evaluated the association between metabolites (predictors) and AD endophenotypes (outcomes). Linear regression was used for continuous AD variables and logistic regression was used for diagnosis. An interaction term between sex and metabolites was included in each model to test whether sex modified the association of metabolites with AD endophenotypes. All models were further sex-stratified when there was evidence of significant sex-metabolite interaction ($P < 0.05$). Each regression model was adjusted for age at sampling, years of education, batch and presence of the *APOE* $\epsilon 4$ allele ($\epsilon 4$ carrier versus no $\epsilon 4$ carrier). The analyses of *APOE* $\epsilon 4$ (+/-) -by- metabolite interaction effects were also conducted using the same approach described above where sex was included as a covariate instead (Supplementary methods and

results). To account for the number of tests performed and the correlations between metabolites, a Bonferroni-adjusted significance threshold ($P < 8.17 \times 10^{-4}$) was set as 0.05 divided by the number of independent metabolites ($n = 61$) from 230 metabolites used in sex-stratified analyses (“independent tests” package in Python https://github.com/hagax8/independent_tests). Exploratory pathway enrichment analyses were additionally performed (Supplementary methods and results).

Individual metabolites showing association with diagnosis ($P < 8.17 \times 10^{-4}$) were investigated as sex-specific biomarkers using prediction models (bootstrapped, $n=1000$, “fbroc” package in R). To evaluate the prediction performance gained by adding sex-specific biomarkers to baseline AD predictors, likelihood ratio test (“lmtest” package in R) was employed followed by net reclassification index (NRI) analysis (“nricens” package in R). The baseline model was built including both CSF biomarkers and covariates. Sex-specific markers were then added, and their performance was evaluated. The prevalence of AD in the dataset (excluding MCI) was utilised as the event rate and participants were categorised into two groups: below and above the event rate. The NRI categorized at the event rate, denoted $NRI(p)$, is a robust measure to model miscalibration (31). We calculated both event NRI and non-event NRI and took the sum as the final $NRI(p)$ (32). It has been reported that adding a variable/variables that has/have a moderate or large effect size (Cohen’s D equal to 0.5 or 0.8, respectively) can yield $NRI(p)$ values between 0.018 and 0.197, depending on the

240 discrimination of the initial model (AUC) (33). To provide insight into the links
241 between diagnosis and other AD endophenotypes, metabolites that were nominally
242 associated with diagnosis and at least one other AD variable were studied further. All
243 statistical analyses were performed using R Studio (version 1.3.1056) unless otherwise
244 stated.

3 Results

3.1 Demographics

The characteristics of the study participants are presented in Table 1. There were no differences in sex distribution among the three diagnostic groups. AD and MCI participants were older compared to CTL participants. There were more *APOE ε4* carriers in the AD group compared to the other two groups ($P < 0.01$). AD participants had lower CSF A β , p-tau, and t-tau z-score levels ($P < 0.01$) compared to the other two groups, which means lower CSF A β_{42} and CSF A $\beta_{42/40}$ ratio. AD participants also had smaller hippocampal volumes (left, right, and sum) and on average smaller cortical thickness in AD signature regions (all, $P < 0.01$). No significant differences were observed for average cortical thickness across the whole brain between the three diagnostic groups ($P \geq 0.05$).

3.2 Sex-specific association of blood metabolites with AD endophenotypes

To identify whether sex modified the association between blood metabolites and the AD endophenotypes included in this study, we built multivariable linear and logistic regression models between each of the 540 metabolite and each of the 15 AD endophenotypes from four collections (CSF biomarkers, brain MRI measurements, cognition measures and diagnosis) by including an interaction term between sex and each metabolite. We found that sex modified the association of 230 metabolites with AD endophenotypes (Supplementary Table S1). Of these, 38 metabolites showed sex-

interactions with CSF biomarkers, 152 with cognition measurements, 79 with brain MRI variables, and 30 with diagnosis (AD/CTL).

Metabolites that showed an interaction with sex at $P < 0.05$ were further investigated for associations with AD endophenotypes in sex-stratified regression analyses. Specifically, only metabolites that showed an interaction with sex in the full dataset, and that associated with the same endophenotype in our sex-stratified analyses, were listed. Stratifying participants by sex revealed that two metabolites, vanillylmandelate (VMA) and tryptophan betaine (Figure 2A & 2B), were associated with AD in females after Bonferroni correction ($P < 8.17 \times 10^{-4}$) ($\beta = 0.77$, 95% CI = 0.40 to 1.18, $P = 1.14 \times 10^{-4}$ and $\beta = -0.73$, 95% CI = -1.12 to -0.36, $P = 1.48 \times 10^{-4}$, respectively), and 116 of 230 metabolites at the nominal significance level. In parallel, one metabolite, kynurenate, was associated with AD in males after Bonferroni correction ($P < 8.17 \times 10^{-4}$) ($\beta = -1.04$, 95% CI = -1.58 to -0.54, $P = 7.63 \times 10^{-5}$) (Table 2) and 100 of 230 metabolites showed nominally significant associations in males (Supplementary Table S1).

In addition to the single metabolite analysis, pathway-based exploratory analysis was performed to provide more insights into these metabolites in AD at a systems level (Supplementary methods and results). We also investigated metabolites that showed sex-specific associations with diagnosis and at least one other AD phenotype ($P < 0.05$). As shown in Figure 1, five metabolites showed associations only in females. These

included isovalerylcarnitine from ‘leucine, isoleucine and valine metabolism’ sub-pathway, carotene diol (1) and carotene diol (2) from ‘vitamin A metabolism’ sub-pathway, as well as phosphatidylcholine (p16:0/16:1), 1-linoleoyl glycerol and methyl 4-hydroxybenzoate sulfate. The above mentioned two sub-pathways were enriched for two collections of endophenotypes, cognition and diagnosis, respectively (Supplementary Table S4). Moreover, six metabolites showed associations in males: lysophosphocholine (18:2) (LPC 18:2), sphingomyelin (d38:0), 5-(galactosylhydroxy)-L-Lysine, kynurenate, N-acetylneuraminate and xanthurenate (Supplementary Figure S2-S12).

3.3 Interactive effect of *APOE* $\epsilon 4$ and sex

After investigating how sex exert metabolite associations with AD endophenotypes, we also performed association analyses for all 540 metabolites with 15 AD endophenotypes from four categories, now stratified by *APOE* $\epsilon 4$ status and adjusted for sex (Supplementary methods and results). Supplementary Table S2 summarises the numbers of number of metabolites showed association with each of the AD endophenotypes in the whole cohort and each *APOE* $\epsilon 4$ +/- stratum. To investigate potential relationships between sex and *APOE* $\epsilon 4$ status on the metabolomic level, we compared the metabolites identified in either sex group and *APOE* $\epsilon 4$ carrier stratification analyses (Supplementary Table S1 and Table S2). There is no overlap of metabolite that associated with the same AD endophenotype between female/male and

APOE $\epsilon 4$ + stratum observed at Bonferroni significance thresholds (Supplementary methods and results).

3.4 Sex-specific metabolites as diagnostic biomarkers

We further explored sex-specific metabolites, VMA, tryptophan betaine, and kynurenate, as diagnostic biomarkers, that were significant following Bonferroni correction in sex stratified regression analyses. In addition, we tested if these three metabolites were associated to drugs ($n = 2$, hydroquinone sulfate and salicylate, sample size $n = 695$), and AD medications ($n = 2$, acetyl -cholinesterase inhibitors or other AD drugs, sample size = 225). Regression models showed no associations between the three metabolites and drugs at $P < 8.17e-04$ (data not shown).

In females, a receiver operating characteristic (ROC) curve (bootstrapped) for VMA and tryptophan betaine was built and is presented in Figure 2C (AUC = 0.83 for AD versus controls, SE = 0.029, 95% CI = 0.777 to 0.889). We then examined how well other AD endophenotypes would discriminate AD cases from controls. CSF biomarkers ($A\beta$, t-tau and p-tau) produced an AUC of 0.89 (SE = 0.025, 95% CI = 0.836 to 0.93), covariates (age at sampling, education years, sampling batch and *APOE* $\epsilon 4$ status) produced an AUC of 0.83 (SE = 0.031, 95% CI = 0.763 to 0.886), CSF biomarkers and covariates together produced AUC of 0.92 (SE = 0.019, 95% CI = 0.881 to 0.954). The combination of the two female-specific biomarkers, CSF biomarkers and covariates

produced AUC of 0.96 (SE = 0.012, 95% CI = 0.93 to 0.978). Bootstrapping results of standard error and 95% confident interval for AUCs from the ROC curves are listed in Supplementary Table S5.

In the male cohort we then built a regression model followed by a ROC curve for kynurenate (Figure 2D). The resulting AUC was 0.68 (SE = 0.046, 95% CI = 0.593 to 0.765). This value was again compared to the CSF biomarkers (AUC = 0.91, SE = 0.026, 95% CI = 0.852 to 0.954), covariates (AUC = 0.77, SE = 0.042, 95% CI = 0.68 to 0.848), both CSF biomarkers & covariates (AUC = 0.932, SE = 0.019, 95% CI = 0.89 to 0.965), and the combination of kynurenate, CSF biomarkers and covariates (AUC = 0.93, SE = 0.02, 95% CI = 0.888 to 0.966). Furthermore, the AUC of CSF biomarkers, covariates, VMA and tryptophan betaine, kynurenate, and combinations of them were explored in the full dataset (males and females combined) (Figure 2E). An increase of AUC from 0.92 to 0.94 was observed when VMA and tryptophan betaine were added to the panel of CSF biomarkers and covariates, while the addition of kynurenate resulted in the same AUC of 0.92 in the full cohort.

Finally, the application of NRI to regression models revealed that, when examining the effect of VMA and tryptophan betaine together in the female sub-dataset, the event NRI, non-event NRI and NRI(p) were 0.04, 0.039, and 0.079 (all above the critical value 0), respectively (Supplementary Figure S13A). However, adding kynurenate to the model in the male sub-dataset yielded nil event NRI, non-event NRI and NRI(p)

350 values (Supplementary Figure S13B). When investigating these sex-specific
 351 biomarkers in the full dataset, an NRI(p) of 0.0516 was observed for the two female-
 352 specific markers, albeit an NRI(p) of -0.0079 was seen for the male-specific marker
 353 (Supplementary Figure S13C & S13D).

4 Discussion

In this study, we measured 665 plasma metabolites in 695 participants: 377 females and 318 males. We used a combination of linear and logistic regression analyses as well as pathway enrichment analyses to investigate sex-specific associations between metabolites and AD endophenotypes. For a follow-up investigation, we found that none of the nine metabolites (four primary fatty acid amides, three amino acids, and two lipokines) demonstrating association with AD in our previous study (16) showed interaction with sex in this study which included an additional 102 participants. Overall, we identified ten sub-pathways that showed sex-specific associations in our exploratory pathway analysis (Supplementary methods and results). A number of metabolites demonstrated associations with clinical AD diagnosis and at least one additional AD clinical biomarker. Finally, we report two metabolites, VMA and tryptophan betaine, which had added value to discriminate in females AD cases from controls and demonstrated improved prediction over traditional CSF biomarkers and covariates (AUC of metabolites = 0.834, AUC of CSF markers = 0.884, AUC of CSF markers & covariates = 0.92, total AUC = 0.955).

4.1 Metabolites associated with AD and other endophenotypes

When we investigated metabolites associated with diagnosis and at least one other AD endophenotype, five out of 11 metabolites showed significant associations in females, namely isovalerylcarnitine, methyl-4-hydroxybenzoate sulfate, carotene diol (1),

carotene diol (2), and 1-lindeoyl glycerol (Figure 1). Among these, isovalerylcarnitine, a short chain acylcarnitine, showed positive associations with cortical thickness in AD regions in females. Moreover, its concentration showed a gradual decrease from cognitively normal group to MCI, and then AD patients. Whilst previous studies have emphasised metabolite links to both sexes, our findings in females are consistent with studies in which sex was not stratified. In these studies, decreased levels of acylcarnitines in schizophrenia and AD were reported (34)(35), although the opposite direction, higher levels of acylcarnitines in subjects with AD have also been observed (36). Carotene diols are unoxygenated carotenoids involved in vitamin A metabolism and we observed decreased levels in AD patients, while other studies have also shown that beta-carotene might protect against dementia (37).

Six metabolites associated with AD and at least one other AD endophenotype in males, namely xanthurenate, N-acetylneuraminate, LPC (18:2), kynurenate, 5-(galactosylhydroxy)-L-lysine, and SM(d38:0). While our study focuses on novel metabolites with association to male sex, links to cognition and AD have been previously reported. Xanthurenate and kynurenate are formed in the kynurenine pathway by tryptophan degradation. They may play a physiological role in attentional and cognitive processes, as well as act as a potential trait marker for schizophrenia (38). The importance of lipid dynamics has been studied as an area of investigation in AD (39). In this regard, we observed significantly increased levels of LPC (18:2) - a

glycerophospholipid - in males, although decreased plasma LPC (18:2) levels have been reported in a non-targeted AD study (40).

4.2 Sex-specific biomarkers

In this study, we found three metabolites, VMA, tryptophan betaine and kynurenine in the tyrosine and tryptophan pathways, to be associated with AD in two sex strata. Kaddurah-Daouk *et al.* found that the level of VMA was elevated in AD versus controls in CSF (41), in accordance with our findings. VMA is an end product of catecholamine metabolism in the tyrosine-dopamine pathway (Supplementary Figure S14A) metabolized by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO) (41). Therefore, the observed increase in positive association with VMA could be the result of the upregulation COMT and/or MAO in female AD patients. Indeed, oestrogen turnover via COMT has been implicated in AD pathogenesis in ApoE-dependent manner (42). In addition, the activation of MAO-B, the alternative pathway to VMA metabolism, has been demonstrated in brains with AD (43).

Tryptophan betaine was the second female-specific AD marker in this study. An important finding of this study is that metabolites that can act via the gut-brain axis showed sex-specific associations. Tryptophan betaine is found in high fibre plants, and it is also linked to microbiota in fibre-enriched diets (44). Koistinen *et al.* found that tryptophan betaine correlated negatively with several bacterial taxa which have earlier been associated with adverse effects in the gut and overall health in an in vitro model

of the human gastrointestinal system (44). It is an indole alkaloid composed of tryptophan and three methyls (Supplementary Figure S14B) and has been found to have neurological and glucose-lowering effects in rodents (45). Interestingly, it has been also been reported as sleep-inducing and anti-inflammatory compound when tested in animal models (45,46). Furthermore, in females, our pathway analyses revealed enrichment in the tryptophan pathway for AD diagnosis (Supplementary methods and results).

Another metabolite in the same pathway and that was decreased in male AD patients specifically was kynurenate. It is produced via a secondary branch of the kynurenine pathway through tryptophan degradation (Supplementary Figure S14B). This is in agreement with studies with no sex-specific analyses, where kynurenine concentrations were decreased in AD plasma/serum (36)(47). In the past it has been reported as an endogenous excitatory amino acid receptor antagonist, as well as a neuroprotective compound (48). Tryptophan is the parent metabolite in both the serotonin and kynurenine pathways. Kynurenate can lead to attenuated glutamate neurotransmission by antagonism of glutamate receptors and release, which consequently decreases glutamate-evoked dopamine release in the striatum (49).

Both pathways, tyrosine-dopamine and tryptophan, have been reported to be linked to inflammation in psychiatric disease (50). The predictive abilities of the two female- and one male-specific biomarkers were initially evaluated by calculating the AUC, and

further assessed by NRI when compared to existing baseline models. NRI(p) of 0.079 and 0.052 were observed for the two female-specific markers in the female dataset and the full dataset (Supplementary Figure S13A & S13C), respectively. With the baseline AUC over 0.9, it has been reported that the effect size (Cohen's D) of adding the female-specific markers could reach 0.8 (33). The increased AUC values, together with positive NRI, support the hypothesis that female-specific AD markers add value to precision medicine (31).

4.3 Limitations and conclusions

A limitation of this study is that, although it is relatively large, the number of participants is still small particularly after sex-stratification. Also, results of this study should be validated in an independent cohort. However, to avoid potential overfitting all AUCs from ROC curves were bootstrapped 1000 times with 95% CIs and standard errors presented. In addition, an important finding of this study is the gut-brain axis link shown by the tryptophan betaine and VMA pathways in females, however no causal implications can be drawn from our study. Additional limitations include survival and selection bias inherent to observational studies. In summary, our study reports sex-specific metabolic differences in AD and highlights two metabolites, both involved in neurotransmission pathways as potential female-specific biomarkers in AD. This is the first report that highlights female-specific and modifiable metabolites associated with AD, paving the way to personalised treatment.

Acknowledgements

The authors thank the participants and families who took part in this research. The authors would also like to thank all people involved in data and sample collection and/or logistics across the different centres.

Funding: The present study was conducted as part of the EMIF-AD project, which has received support from the Innovative Medicines Initiative Joint Undertaking under EMIF grant agreement no. 115372, EPAD grant no. 115736, and from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 666992. Resources of which are composed of financial contribution from the European Union's Seventh Framework Program (FP7/2007-2013) and EFPIA companies' in-kind contribution. The DESCRIPA study was funded by the European Commission within the fifth framework program (QLRT-2001-2455). The EDAR study was funded by the European Commission within the fifth framework program (contract no. 37670). The San Sebastian GAP study is partially funded by the Department of Health of the Basque Government (allocation 17.0.1.08.12.0000.2.454.01.41142.001.H). The Leuven cohort was funded by the Stichting voor Alzheimer Onderzoek (grant numbers #11020, #13007 and #15005). The SPIN cohort (Barcelona) has received funding from CIBERNED; Instituto de Salud Carlos III; jointly funded by Fondo Europeo de Desarrollo Regional (FEDER), Unión Europea, “Una manera de hacer Europa”; Generalitat de Catalunya; Fundació "La Marató TV3" Fundació Bancària Obra Social

480 La Caixa; Fundación BBVA; Fundación Española para el Fomento de la Investigación
481 de la Esclerosis Lateral Amiotrófica (FUNDELA); Global Brain Health Institute;
482 Fundació Catalana Síndrome de Down; and Fundació Víctor Grífols i Lucas. KB and
483 HZ are Wallenberg Scholars supported by grants from the Swedish Research Council
484 (#2017-009152018-02532), the European Research Council (#681712), Swedish State
485 Support for Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery
486 Foundation (ADDF), USA (#RDAPB-201809-2016615), the Swedish
487 Alzheimer2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-
488 21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C), the Olav Thon
489 Foundation (#AF-742881), the Erling-Persson Family Foundation, Stiftelsen för Gamla
490 Tjänarinnor, Hjärnfonden, Sweden (#FO2017-0243), the Swedish stateFO2019-0228),
491 the European Union's Horizon 2020 research and innovation programme under the
492 Marie Skłodowska-Curie grant agreement between the Swedish government and the
493 County Councils, the ALF-agreement (#ALFGBG-715986), the European Union Joint
494 Program for Neurodegenerative Disorders (JPND2019-466-236No 860197
495 (MIRIADE), and the National UK Dementia Research Institute at UCL. Research at
496 VIB-Antwerp was in part supported by the University of Health (NIH), USA (grant
497 #1R01AG068398-01) Antwerp Research Fund. PK is supported by the Swedish state
498 under the agreement between the Swedish government and the County Councils, the
499 ALF-agreement ALFGBG-724331 and AW by ALFGBG-720661. DJM was partially
500 supported by a grant from the National Institutes of Health (R15-GM107864). YFL is

501 supported by The Brain Foundation (Hjärnfonden FO2018-0315), Stohne's Foundation
502 (Stohnes Stiftelse), Gamla Tjänarinnor Stftelse, Stohnes Stiftelse, Särfond 31S
503 Research Fund Region Örebro län Sweden, Familjen Kamprad Stiftelse (ref 20210034,
504 AFA 200386). DA received support from Institute of Health Carlos III (ISCIII),
505 Spain PI18/00435 and INT19/00016, and by the Department of Health
506 Generalitat de Catalunya PERIS program SLT006/17/125. JL is funded by the van
507 Geest endowment fund. RG is funded by the National Institute for Health Research
508 (NIHR) Biomedical Research Centre. JX and CLQ thank Lundbeck Fonden for the
509 support.

Tables

Table 1. Sample demographics.

	Sample size	CTL	MCI	AD	P- value*
Age	695	65 (7.9)	70 (8.1)	70 (8.49)	6.52e-14
Sex (f/m)	377/318	155/128	141/134	81/56	3.13e-01
<i>APOE</i> $\epsilon 4$ (+/-)	348/347	111/172	153/122	84/53	7.30e-06
A β z-score	693	-0.22 (1.11)	-0.82 (0.99)	-1.22 (0.64)	<2.00e-16
p-tau z-score	640	-0.00087 (0.99)	-0.94 (1.38)	-1.31 (1.66)	<2.00e-16
t-tau z-score	637	0.032 (0.84)	-0.98 (1.25)	-1.65 (1.60)	<2.00e-16
Attention z-score	644	0.21 (1.13)	-0.91 (1.63)	-1.92 (1.99)	<2.00e-16
Executive z-score	526	0.16 (1.16)	-0.79 (2.04)	-2.26 (2.55)	<2.00e-16
Language z-score	674	-0.18 (0.99)	-1.0 (1.25)	-2.08 (1.27)	<2.00e-16
Memory delayed z-score	551	-0.037 (1.15)	-1.52 (1.40)	-2.40 (1.070)	<2.00e-16
Memory immediate z-score	637	-0.50 (1.77)	-1.57 (1.39)	-2.34 (1.24)	<2.00e-16
Visuo-construction z-score	436	-0.20 (1.34)	-0.14 (1.47)	-1.36 (1.98)	1.93e-08
Hippocampal left	455	3761.21 (453.57)	3272.52 (634.570)	3017.90 (487.63)	<2.00e-16
Hippocampal right	455	3878.12 (436.76)	3388.14 (628.15)	3146.17 (500.52)	<2.00e-16
Hippocampal sum	455	7639.32 (857.95)	6660.69 (1210.53)	6182.10 (913.81)	<2.00e-16
Cortical thickness in whole brain	420	2.30 (0.12)	2.30 (0.11)	2.28 (0.11)	5.47e-01
Cortical thickness in AD regions	420	2.66 (0.16)	2.63 (0.15)	2.58 (0.17)	1.95e-04
Taking AChEI, yes/no	76/149	1/40	50/78	25/31	1.3e-05
Taking other AD medications, yes/no	23/201	0/41	16/112	7/48	1.55e-01

Results are mean (standard deviation) for continuous variables.

A β , amyloid beta; AChEI, acetylcholine esterase inhibitor; AD, Alzheimer's disease; APOE $\epsilon 4$, apolipoproteinE $\epsilon 4$; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; CTL, control; ROD, rate of cognitive decline.

*Differences in the means/frequencies of clinical/demographic variables were tested using ANOVA or χ^2 test.

Table 2. Association results for metabolites in relation to diagnosis (AD/CTL) in the full cohort and after stratification by sex.

<i>Metabolite</i>	<i>Interaction effect</i>	<i>Interaction P-value</i>	<i>Female effect</i>	<i>Female P-value</i>	<i>95% CI</i>	<i>Male effect</i>	<i>Male P-value</i>	<i>95% CI</i>
VMA	0.84	1.66e-03	0.77	1.14e-04	0.04 to 1.18	-0.16	0.438	
Tryptophan betaine	-0.58	1.92e-02	-0.73	1.48e-04	-1.12 to 0.36	-0.015	0.934	
Kynurenate	0.69	2.35e-02	0.37	0.043		-1.04	7.63e-05	-1.58 to 0.54

AD, Alzheimer's disease; CTL, controls, VMA, vanillylmandelate.

521 **Figures**

522

523

524 **Figure 1. Eleven metabolites showed associations with AD and one other**
525 **endophenotype.** Five plasma metabolites (with brown grid), isovalerylcarnitine,
526 methyl 4-, carotene diol (2), 1-linoleoyl glycerol and carotene diol (1), were
527 significantly associated with diagnosis and the other AD endophenotypes in female
528 group only. Six other metabolites (with blue grid), xanthurenate, N-acetylneuraminic acid,
529 LPC (18:2), kynurenine, 5-(galactosylhydroxy)-L-lysine and SM (d38:0), showed
530 associations with diagnosis and AD variables in male group only.

Figure 2. Box plots of two female biomarkers A) vanillylmandelate and B) tryptophan betaine, the p value (below Bonferroni significance threshold) and the association coefficient (beta) for metabolites in relation to diagnosis (AD/CTL) are shown above the box plots; ROC graphs, comparing area under curve (AUC) in predictive models using sex-specific biomarkers, CSF biomarkers, covariates, and the combination of them in C) the female sub-dataset; D) the male sub-dataset; E) the full cohort; F) Bar plot summarises the AUC of the above mentioned ROC curves together with standard errors after bootstrapping.

References

1. Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chtelat G, Teunissen CE, et al. Alzheimer's disease. The Lancet [Internet]. 2021 Mar 2 [cited 2021 Mar 3]; Available from: <https://www.sciencedirect.com/science/article/pii/S0140673620322054>
2. Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimers Dement J Alzheimers Assoc*. 2018;14(4):535–62.
3. Jack CR, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. *Neurology*. 2016 Aug 2;87(5):539–47.
4. Vinters HV. Emerging Concepts in Alzheimer's Disease. *Annu Rev Pathol Mech Dis*. 2015 Jan 24;10(1):291–319.
5. Pike CJ. Sex and the development of Alzheimer's disease. *J Neurosci Res*. 2017 Jan 2;95(1–2):671–80.
6. Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. *Lancet Neurol*. 2020;19(5):422–33.
7. Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. *JAMA*. 2020 Aug 25;324(8):772–81.
8. Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study - The Lancet Healthy Longevity [Internet]. [cited 2021 Mar 15]. Available from: [https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568\(20\)30061-1/fulltext](https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(20)30061-1/fulltext)
9. Xu W, Tan L, Wang H-F, Jiang T, Tan M-S, Tan L, et al. Meta-analysis of modifiable risk factors for Alzheimer's disease. *J Neurol Neurosurg Psychiatry*. 2015 Dec;86(12):1299–306.
10. Ruigrok ANV, Salimi-Khorshidi G, Lai M-C, Baron-Cohen S, Lombardo MV, Tait RJ, et al. A meta-analysis of sex differences in human brain structure. *Neurosci Biobehav Rev*. 2014 Feb;39:34–50.

- 573 11. Mielke MM. Sex and Gender Differences in Alzheimer's Disease Dementia.
574 Psychiatr Times. 2018 Nov;35(11):14–7.
- 575 12. Ferretti MT, Iulita MF, Cavedo E, Chiesa PA, Schumacher Dimech A,
576 Santucci Chadha A, et al. Sex differences in Alzheimer disease — the gateway
577 to precision medicine. Nat Rev Neurol. 2018 Aug 1;14(8):457–69.
- 578 13. Dementia UK: Update [Internet]. [cited 2020 Aug 28]. Available from:
579 https://www.alzheimers.org.uk/sites/default/files/migrate/downloads/dementia_u
580 [k_update.pdf](https://www.alzheimers.org.uk/sites/default/files/migrate/downloads/dementia_u)
- 581 14. Evaluation of Selective Survival and Sex/Gender Differences in Dementia
582 Incidence Using a Simulation Model | Dementia and Cognitive Impairment |
583 JAMA Network Open | JAMA Network [Internet]. [cited 2021 Mar 22]. Available
584 from:
585 [https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777217?utm_so](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777217?utm_source=twitter&utm_campaign=content-shareicons&utm_content=article_engagement&utm_medium=social&utm_term=031121#.YEob6Li2E7w.twitter)
586 [urce=twitter&utm_campaign=content-](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777217?utm_source=twitter&utm_campaign=content-shareicons&utm_content=article_engagement&utm_medium=social&utm_term=031121#.YEob6Li2E7w.twitter)
587 [shareicons&utm_content=article_engagement&utm_medium=social&utm_term](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777217?utm_source=twitter&utm_campaign=content-shareicons&utm_content=article_engagement&utm_medium=social&utm_term=031121#.YEob6Li2E7w.twitter)
588 [=031121#.YEob6Li2E7w.twitter](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777217?utm_source=twitter&utm_campaign=content-shareicons&utm_content=article_engagement&utm_medium=social&utm_term=031121#.YEob6Li2E7w.twitter)
- 589 15. Stamate D, Kim M, Proitsi P, Westwood S, Baird A, Nevado-Holgado A, et al. A
590 metabolite-based machine learning approach to diagnose Alzheimer-type
591 dementia in blood: Results from the European Medical Information Framework
592 for Alzheimer disease biomarker discovery cohort. Alzheimers Dement Transl
593 Res Clin Interv. 2019 Dec 18;5:933–8.
- 594 16. Kim M, Snowden S, Suvitaival T, Ali A, Merkler DJ, Ahmad T, et al. Primary
595 fatty amides in plasma associated with brain amyloid burden, hippocampal
596 volume, and memory in the European Medical Information Framework for
597 Alzheimer's Disease biomarker discovery cohort. Alzheimers Dement. 2019 Jun
598 1;15(6):817–27.
- 599 17. Bos I, Vos S, Vandenberghe R, Scheltens P, Engelborghs S, Frisoni G, et al. The
600 EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort
601 characteristics. Alzheimers Res Ther. 2018 Jul 6;10(1):64.
- 602 18. Reijls BLR, Ramakers IHGB, Elias-Sonnenschein L, Teunissen CE, Koel-
603 Simmelink M, Tsolaki M, et al. Relation of Odor Identification with Alzheimer's
604 Disease Markers in Cerebrospinal Fluid and Cognition. J Alzheimers Dis JAD.
605 2017;60(3):1025–34.
- 606 19. Galluzzi S, Marizzoni M, Babiloni C, Albani D, Antelmi L, Bagnoli C, et al.
607 Clinical and biomarker profiling of prodromal Alzheimer's disease in
608 workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a
609 'European ADNI study'. J Intern Med. 2016;279(6):576–91.

- 610 20. Visser PJ, Verhey FRJ, Boada M, Bullock R, De Deyn PP, Frisoni GB, et al.
611 Development of Screening Guidelines and Clinical Criteria for Predementia
612 Alzheimer's Disease. *Neuroepidemiology*. 2008 Jun;30(4):254–65.
- 613 21. van der Flier WM, Pijnenburg YAL, Prins N, Lemstra AW, Bouwman FH,
614 Teunissen CE, et al. Optimizing patient care and research: the Amsterdam
615 Dementia Cohort. *J Alzheimers Dis JAD*. 2014;41(1):313–27.
- 616 22. Somers C, Struyfs H, Goossens J, Niemantsverdriet E, Luyckx J, De Roeck N, et
617 al. A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in
618 Belgium. *J Alzheimers Dis JAD*. 2016 10;54(1):383–95.
- 619 23. Fortea J, Sala-Llloch R, Bartrés-Faz D, Bosch B, Lladó A, Bargalló N, et al.
620 Increased cortical thickness and caudate volume precede atrophy in PSEN1
621 mutation carriers. *J Alzheimers Dis JAD*. 2010;22(3):909–22.
- 622 24. Adamczuk K, Schaefferbeke J, Nelissen N, Neyens V, Vandenbulcke M, Goffin
623 K, et al. Amyloid imaging in cognitively normal older adults: comparison between
624 (18)F-flutemetamol and (11)C-Pittsburgh compound B. *Eur J Nucl Med Mol*
625 *Imaging*. 2016 Jan;43(1):142–51.
- 626 25. Estanga A, Ecay-Torres M, Ibañez A, Izagirre A, Villanua J, Garcia-Sebastian M,
627 et al. Beneficial effect of bilingualism on Alzheimer's disease CSF biomarkers
628 and cognition. *Neurobiol Aging*. 2017 Feb 1;50:144–51.
- 629 26. Alcolea D, Clarimón J, Carmona-Iragui M, Illán-Gala I, Morenas-Rodríguez E,
630 Barroeta I, et al. The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A
631 data set for biomarker discovery and validation in neurodegenerative disorders.
632 *Alzheimers Dement Transl Res Clin Interv*. 2019 Oct 14;5:597–609.
- 633 27. Wallin A, Nordlund A, Jonsson M, Blennow K, Zetterberg H, Öhrfelt A, et al.
634 Alzheimer's disease--subcortical vascular disease spectrum in a hospital-based
635 setting: Overview of results from the Gothenburg MCI and dementia studies. *J*
636 *Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab*. 2016
637 Jan;36(1):95–113.
- 638 28. Tautvydaitė D, Kukreja D, Antonietti J-P, Henry H, von Gunten A, Popp J.
639 Interaction between personality traits and cerebrospinal fluid biomarkers of
640 Alzheimer's disease pathology modulates cognitive performance. *Alzheimers Res*
641 *Ther*. 2017 Feb 2;9(1):6.
- 642 29. Petersen RC. Mild cognitive impairment as a diagnostic entity. *J Intern Med*. 2004
643 Sep;256(3):183–94.

- 644 30. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical
645 diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group
646 under the auspices of Department of Health and Human Services Task Force on
647 Alzheimer's Disease. *Neurology*. 1984 Jul;34(7):939–44.
- 648 31. Thomas LE, O'Brien EC, Piccini JP, D'Agostino RB, Pencina MJ. Application of
649 net reclassification index to non-nested and point-based risk prediction models: a
650 review. *Eur Heart J*. 2019 Jun 14;40(23):1880–7.
- 651 32. Pencina MJ, D'Agostino RB, D'Agostino RB, Vasan RS. Evaluating the added
652 predictive ability of a new marker: from area under the ROC curve to
653 reclassification and beyond. *Stat Med*. 2008 Jan 30;27(2):157–72; discussion 207-
654 212.
- 655 33. Pencina MJ, Steyerberg EW, D'Agostino RB. Net reclassification index at event
656 rate: properties and relationships. *Stat Med*. 2017;36(28):4455–67.
- 657 34. Serum Levels of Acyl-Carnitines along the Continuum from Normal to
658 Alzheimer's Dementia [Internet]. [cited 2020 Sep 17]. Available from:
659 <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0155694>
- 660 35. Characterizing acyl-carnitine biosignatures for schizophrenia: a longitudinal pre-
661 and post-treatment study | Translational Psychiatry [Internet]. [cited 2020 Sep 17].
662 Available from: <https://www.nature.com/articles/s41398-018-0353-x>
- 663 36. van der Velpen V, Teav T, Gallart-Ayala H, Mehl F, Konz I, Clark C, et al.
664 Systemic and central nervous system metabolic alterations in Alzheimer's disease.
665 *Alzheimers Res Ther*. 2019 Nov 28;11(1):93.
- 666 37. von Arnim CAF, Herbolzheimer F, Nikolaus T, Peter R, Biesalski HK, Ludolph
667 AC, et al. Dietary antioxidants and dementia in a population-based case-control
668 study among older people in South Germany. *J Alzheimers Dis JAD*.
669 2012;31(4):717–24.
- 670 38. Giil LM, Midttun Ø, Refsum H, Ulvik A, Advani R, Smith AD, et al. Kynurenine
671 Pathway Metabolites in Alzheimer's Disease. *J Alzheimers Dis JAD*.
672 2017;60(2):495–504.
- 673 39. Wood PL. Lipidomics of Alzheimer's disease: current status. *Alzheimers Res*
674 *Ther*. 2012 Feb 1;4(1):5.
- 675 40. Li N, Liu W, Li W, Li S, Chen X, Bi K, et al. Plasma metabolic profiling of
676 Alzheimer's disease by liquid chromatography/mass spectrometry. *Clin Biochem*.
677 2010 Aug;43(12):992–7.

- 678 41. Kaddurah-Daouk R, Zhu H, Sharma S, Bogdanov M, Rozen SG, Matson W, et al.
679 Alterations in metabolic pathways and networks in Alzheimer's disease. *Transl*
680 *Psychiatry*. 2013 Apr 9;3:e244.
- 681 42. Martínez MF, Martín XE, Alcelay LG, Flores JC, Valiente JMU, Juanbeltz BI, et
682 al. The COMT Val158 Met polymorphism as an associated risk factor for
683 Alzheimer disease and mild cognitive impairment in APOE 4 carriers. *BMC*
684 *Neurosci*. 2009 Sep 30;10:125.
- 685 43. Gulyás B, Pavlova E, Kása P, Gulya K, Bakota L, Várszegi S, et al. Activated
686 MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl
687 using whole hemisphere autoradiography. *Neurochem Int*. 2011 Jan;58(1):60–8.
- 688 44. Koistinen VM, Kärkkäinen O, Borewicz K, Zarei I, Jokkala J, Micard V, et al.
689 Contribution of gut microbiota to metabolism of dietary glycine betaine in mice
690 and in vitro colonic fermentation. *Microbiome*. 2019 Jul 10;7(1):103.
- 691 45. Aswad M, Rayan M, Abu-Lafi S, Falah M, Raiyn J, Abdallah Z, et al. Nature is
692 the best source of anti-inflammatory drugs: indexing natural products for their
693 anti-inflammatory bioactivity. *Inflamm Res Off J Eur Histamine Res Soc Al*. 2018
694 Jan;67(1):67–75.
- 695 46. Sun H, Cai W, Wang X, Liu Y, Hou B, Zhu X, et al. Vaccaria hypaphorine
696 alleviates lipopolysaccharide-induced inflammation via inactivation of NFκB and
697 ERK pathways in Raw 264.7 cells. *BMC Complement Altern Med*. 2017 Feb
698 20;17(1):120.
- 699 47. Hartai Z, Juhász A, Rimanóczy Á, Janáky T, Donkó T, Dux L, et al. Decreased
700 serum and red blood cell kynurenic acid levels in Alzheimer's disease. *Neurochem*
701 *Int*. 2007 Jan 1;50(2):308–13.
- 702 48. Gulaj E, Pawlak K, Bien B, Pawlak D. Kynurenine and its metabolites in
703 Alzheimer's disease patients. *Adv Med Sci*. 2010 Jan 1;55(2):204–11.
- 704 49. Poeggeler B, Rassoulpour A, Wu H-Q, Guidetti P, Roberts RC, Schwarcz R.
705 Dopamine receptor activation reveals a novel, kynurenate-sensitive component of
706 striatal N-methyl-d-aspartate neurotoxicity. *Neuroscience*. 2007 Aug
707 10;148(1):188–97.
- 708 50. Raison CL, Rook GW, Miller AH, Begay TK. Chapter 26 - Role of Inflammation
709 in Psychiatric Disease. In: Zigmond MJ, Rowland LP, Coyle JT, editors.
710 *Neurobiology of Brain Disorders* [Internet]. San Diego: Academic Press; 2015
711 [cited 2021 Jan 12]. p. 396–421. Available from:
712 <http://www.sciencedirect.com/science/article/pii/B9780123982704000264>

Appendix

List of collaborators in European Medical Information Framework (EMIF)

consortium.

Organisations	Partner type	Country
Aarhus Universitetshospital	Academia	Denmark
Agenzia Regionale di Sanità	Academia	Italy
Alzheimer Europe	Patient Organisation	Luxembourg
Amgen	EFPIA	UK
Boehringer Ingelheim International GmbH	EFPIA	Germany
Cambridge Cognition Ltd	SME	UK
Concentris Research Management GmbH	SME	Germany
Custodix NV	SME	Belgium
Electrophoretics Ltd	SME	UK
Erasmus Universitair Medisch Centrum Rotterdam	Academia	The Netherlands
European Institute for Health Records	Academia	Belgium
European Molecular Biology Laboratory	Academia	Germany
F. Hoffmann-La Roche AG	EFPIA	Switzerland
Fondazione PENTA - for the Treatment and Care of Children with HIV-ONLUS	Academia	Italy
Genomedics S.R.L.	Academia	Italy
GlaxoSmithKline Research and Development Ltd	EFPIA	UK
Göteborgs Universitet	Academia	Sweden
Helsingin Yliopisto	Academia	Finland
IDIAP	Academia	Spain
Institut National de la Santé et de la Recherche Médicale	Academia	France
Itä-Suomen Yliopisto	Academia	Finland
Janssen Pharmaceutica NV	EFPIA	Belgium
Karolinska Institutet	Academia	Sweden
King's College London	Academia	UK
Leibniz Institute for Prevention, Research and Epidemiology - BIPS GmbH	Academia	Germany
Maastricht University	Academia	The Netherlands

MAAT France	SME	France
Merck	EFPIA	Germany
Novo Nordisk A/S	EFPIA	Denmark
Pedianet	SME	Italy
Pfizer	EFPIA	UK
Pharmo Cooperatie UA	SME	The Netherlands
Provincia Lombardo-Veneta - Ordine Ospedaliero di San Giovanni di Dio— Fatebenefratelli	Academia	Italy
Servier	EFPIA	France
Synapse Research Management Partners S.L.	SME	Spain
Tartu Ulikool	Academia	Estonia
Teknologian tutkimuskeskus VTT	Academia	Finland
UCB Pharma SA	EFPIA	Belgium
Universidade de Aveiro	Academia	Portugal
Universitat Pompeu Fabra	Academia	Spain
Universiteit Antwerpen	Academia	Belgium
University College London	Academia	UK
University of Copenhagen	Academia	Denmark
University of Exeter	Academia	UK
University of Glasgow	Academia	UK
University of Leicester	Academia	UK
University of Manchester	Academia	UK
University of Oxford	Academia	UK
University Pierre et Marie Curie	Academia	France
Università degli Studi di Pisa	Academia	Italy
Universität Leipzig	Academia	Germany
Universität zu Lübeck (University of Lübeck)	Academia	Germany
Universitätsklinikum Erlangen, Anstalt des Öffentlichen Rechts	Academia	Germany
Vestische Kinder - und Jugendklinik Datteln	Academia	Germany
VIB	Academia	Belgium
VU University Medical Center	Academia	The Netherlands